Murali Janakiram
ECOG-ACRIN Cancer Research Group · City of Hope Medical Center · University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Murali Janakiram as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:01 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07463807 · Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentNational Cancer Institute (NCI) · recruiting · Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1NCT06048250 · Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaCity of Hope Medical Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT03081780 · Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLMasonic Cancer Center, University of Minnesota · completed · Refractory Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia · principal investigator
- N/ANCT01899326 · Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell TransplantAlbert Einstein College of Medicine · terminated · DS (Durie/Salmon) Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2017 to 2026Named on NCT07463807
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2017 to 2026Named on NCT06048250
- Biostatistics Shared ResourceP30CA013330 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI XIAONAN NA XUE · fiscal years 2017 to 2026Named on NCT01899326
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:01 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- 524 citationsRCR 26.6
- Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.N Engl J Med · 2018200 citationsRCR 6.6
- Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.Blood · 201996 citationsRCR 3.3
- An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.Appl Immunohistochem Mol Morphol · 201827 citationsRCR 0.9
- Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.J Clin Oncol · 202616 citationsRCR 8.0